Sign in

Matt Dellatorre

Vice President and Equity Analyst at Goldman Sachs Group Inc.

Matt Dellatorre is a Vice President and Equity Analyst at Goldman Sachs, specializing in coverage of the generic pharmaceuticals and biotechnology sectors. He formally covers companies such as Viatris and has issued ratings including a recent 'Neutral' initiation, though his tracked performance metrics indicate a 0% success rate and an average return of -7.5% over the last rating cycle. Dellatorre began his analyst career at Goldman Sachs in 2020 after earning a doctorate degree, and previously worked as an Associate before advancing to his current leadership role. He holds professional FINRA registrations and securities licenses, including CRD# 7174007, and is based out of Goldman Sachs’s Washington, DC office.

Matt Dellatorre's questions to Viatris (VTRS) leadership

Question · Q3 2025

Matt Dellatorre asked for feedback from the FDA regarding a potential opioid-sparing label for fast-acting meloxicam and its significance for access and pricing. He also questioned the partnership strategy for broader market reach, including value split and deal structure, and Viatris's capital allocation priorities for 2026, specifically regarding US-based business development and midsize licensing deals.

Answer

Chief R&D Officer Philippe Martin discussed meloxicam's opioid-sparing label, confirming the phase III study was designed with FDA collaboration and expressing confidence in the strong data. CEO Scott Smith stated Viatris is exploring partnership discussions for meloxicam but is prepared to commercialize it independently if a partnership isn't significantly additive. He reiterated a balanced capital allocation approach over a three-to-five-year period, aiming for 50/50 return to shareholders and growth asset building, noting a focus on share buybacks in 2025 and a desire for in-market, accretive U.S.-based innovative products.

Ask follow-up questions

Question · Q3 2025

Matt Dellatorre asked about FDA feedback on fast-acting meloxicam's potential opioid-sparing label and its impact on access/pricing. He also inquired about the partnership strategy for broader market reach, including value split, and Viatris's 2026 capital allocation priorities, particularly for U.S.-based, mid-sized licensing deals.

Answer

Chief R&D Officer Philippe Martin confirmed the phase 3 study for fast-acting meloxicam was designed for opioid-sparing language, with strong data supporting this goal. CEO Scott Smith noted active partnership discussions but emphasized Viatris's capability to commercialize independently if a partnership isn't significantly additive. For 2026 capital allocation, Scott Smith reiterated a balanced, long-term approach (50/50 return vs. growth assets), including in-market, accretive U.S. innovative products, with yearly mix depending on opportunities.

Ask follow-up questions

Question · Q2 2025

Matt Dellatorre of Goldman Sachs inquired about Viatris's capital allocation strategy, the balance between share buybacks and business development (BD), and the company's long-term growth targets for 2026 and beyond.

Answer

CEO Scott Smith stated that the capital allocation plan remains balanced between shareholder returns and strategic, accretive BD to build a growth portfolio. He highlighted upcoming product launches and pipeline readouts as key organic growth drivers, declining to provide a specific 2026 growth target. CFO Doretta Mistras added that the base business is expected to generate low single-digit revenue growth, with BD investments being additive to that baseline.

Ask follow-up questions

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%